Opinion
Video
LITESPARK-003 Trial Insights: Updates from ESMO 2023
An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the LITESPARK-003 phase 2 trial evaluating belzutifan plus cabozantinib in advanced RCC. Belzutifan is a HIF-2α inhibitor approved for Von Hippel–Lindau disease–associated RCC. The LITESPARK-003 trial had 2 cohorts; cohort 1 was first-line, and cohort 2 was subsequent line therapy.
Cohort 1 included 50 patients with favorable risk, whereas cohort 2 had 51 patients with intermediate/poor risk. At a median follow-up of 2 years in cohort 1 and 40 months in cohort 2, median overall survival was not reached in cohort 1 and was 26.7 months in cohort 2. The combination showed antitumor activity and was fairly well tolerated, with no treatment-related deaths.
Daneshmand notes that although these are exciting results, determining the optimal place for belzutifan combinations within the evolving RCC treatment landscape of multiple combinations therapies remains to be seen. Nonetheless, having additional active targeted therapy options is positive.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
